Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on March 8, 2018. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the period ended December 31, 2017.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the March 8, 2018 press release), as they are not present in the 8-K text.
- Confirm the company name is Imprimis Pharmaceuticals, Inc., noting the discrepancy with the metadata field "HARROW, INC."
- Review the press release for any forward-looking statements or clinical trial updates that may impact future valuation.
- Check subsequent filings for any updates to the financial condition, as the company disclaims an obligation to update this specific report.